Drug Profile
HTI 501
Alternative Names: HTI-501; Recombinant human cathepsin L - Halozyme Therapeutics; rHuCAT-LLatest Information Update: 18 Dec 2019
Price :
$50
*
At a glance
- Originator Halozyme Therapeutics
- Class
- Mechanism of Action Cathepsin L modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cellulite